Holen Sie sich die Stockscreener-App
170.56
2.95%
-5.181
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Pitcairn Co. Acquires Shares of 7,454 Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Valuation Check After Positive Neurology Data for Lecanemab and Zorevunersen - simplywall.st
Biogen Inc. (NASDAQ:BIIB) Doing What It Can To Lift Shares - 富途牛牛
Biogen’s New Study on BIIB145: A Potential Game-Changer for MS Treatment? - TipRanks
Alzheimer’s Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Biogen, Eisai, Eli Lilly and Company, AB Science, Alzheon, Inc., Cerecin, BioVie, Eisai Inc - Barchart.com
Biogen Doubles Down On Immunology As Lupus Programs Near Readouts - Citeline News & Insights
Biogen: Alzheimer's Disease Treatment Needs More Real-World Data (NASDAQ:BIIB) - Seeking Alpha
Hudson Bay Capital Management LP Buys 67,220 Shares of Biogen Inc. $BIIB - MarketBeat
Hudson Bay Capital Management LP Has $33.63 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - Seeking Alpha
Biogen Inc. $BIIB Shares Purchased by Balyasny Asset Management L.P. - MarketBeat
Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index - marketscreener.com
Key facts: Biogen to release tau drug data; Morgan Stanley raises target; Jefferies hints at Nasdaq 100 removal - TradingView
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial - GlobeNewswire Inc.
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BII - GuruFocus
Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating - marketscreener.com
Boards of Appeal revoke Biogen’s dosage patent for Tecfidera - JUVE Patent
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - marketscreener.com
State Street Corp Raises Position in Biogen Inc. $BIIB - MarketBeat
United States Controlled Release Drug Delivery Market to Reach - openPR.com
Axa S.A. Sells 45,397 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc (NASDAQ:BIIB) Nasdaq Composite ETF Neuro Innovation - Kalkine Media
Forecast 2035: Alzheimers Disease Diagnostic Market Size Set - openPR.com
Biogen (BIIB) Is Down 5.2% After HSBC Downgrade Amid Mixed Drug Pipeline Signals – Has The Bull Case Changed? - simplywall.st
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS - BioSpace
Federated Hermes Inc. Acquires 17,069 Shares of Biogen Inc. $BIIB - MarketBeat
Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential - Yahoo Finance
Wells Fargo Maintains Biogen (BIIB) Equal-Weight Recommendation - Nasdaq
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating - GuruFocus
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns - GuruFocus
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma - MSN
AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) - Seeking Alpha
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Here are Wednesday’s top Wall Street analyst research calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and more - MSN
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - Yahoo Finance
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - 24/7 Wall St.
Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating - marketscreener.com
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News - GuruFocus
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada - BioSpace
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… - marketscreener.com
HSBC Downgrades Biogen to Reduce From Hold, Adjusts Price Target to $143 From $144 - marketscreener.com
California Public Employees Retirement System Sells 46,044 Shares of Biogen Inc. $BIIB - MarketBeat
HSBC downgrades Biogen stock rating to Reduce on royalty concerns - Investing.com
Is Biogen’s Recent 20% Rally Just the Start as Valuation Signals Turn Attractive? - simplywall.st
Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Is Biogen stock outperforming the Dow? - MSN
symbol__ Stock Quote Price and Forecast - CNN
Marshall Wace LLP Boosts Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen (SUPN) gains Health Canada NOC for ZURZUVAE in postpartum depression treatment - Stock Titan
Amundi Cuts Position in Biogen Inc. $BIIB - MarketBeat
Eisai and Biogen's LEQEMBI® Added to China's Commercial Insurance Innovative Drug List, Enhancing Access to Alzheimer's Treatment - Quiver Quantitative
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List - Biogen
Biogen (BIIB): Assessing Valuation After Promising New Zorevunersen Data in Dravet Syndrome - simplywall.st
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? - The Globe and Mail
Is Biogen Stock Outperforming the Dow? - Yahoo Finance
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 - marketscreener.com
Invesco Ltd. Increases Stock Position in Biogen Inc. $BIIB - MarketBeat
Lido Advisors LLC Has $647,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stake Reduced by Schroder Investment Management Group - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Biogen Inc. $BIIB Shares Bought by Guggenheim Capital LLC - MarketBeat
First Trust Advisors LP Acquires 212,403 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
BIIB: Promising Data for Biogen's Zorevunersen in Dravet Syndrome Treatment - GuruFocus
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
0.37%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):